Skip to content

    Aether Industri.

    AETHER
    Chemicals·3 Feb 2026
    Management Summary

    Aether Industri. reported strong Q3 FY26 results with significant YoY growth in revenue, EBITDA, and PAT, driven by robust demand and strategic expansions. The company completed construction of Site 3++ and Site 5, with commercial production imminent. While working capital increased due to inventory buildup for new plants, management remains confident in its long-term strategic partnerships and R&D-led growth in specialty chemicals.

    Highlights

    5
    • Consolidated Revenue from operations for Q3 FY26 increased 44% YoY to INR3,171 million.

    • EBITDA for Q3 FY26 grew 75% YoY to INR1,083 million, with EBITDA margin expanding to 34%.

    • PAT for Q3 FY26 increased 49% YoY to INR645 million, achieving a PAT margin of 20%.

    • Construction and installation of Site 3++ and the first two production blocks of Site 5 are completed, with commercial production commencing shortly.

    • Large-scale manufacturing business vertical saw volume growth of over 10% QoQ and over 25% YoY.

    Concerns

    2
    • Net working capital cycle increased to 160 days from 149 days (Sep 30, 2025) mainly due to inventory buildup for the upcoming start of Site 3++ and Site 5.

    • A one-time FLOP claim of INR15 crores was classified in 'other revenue', temporarily impacting reported margins, which are otherwise guided to be conservatively 29-30%.

    What Changed2

    vs Q4 FY26

    Guidance items11 → 8 (-3)Risks discussed1 → 3 (+2)
    Key financials

    Metrics

    9

    Periods

    2

    Headline

    5
    • Consolidated Revenue
      3,171 Mn
      YoY+44%
    • Consolidated EBITDA
      1,083 Mn
      YoY+75%
    • EBITDA Margin
      34%
    • Consolidated PAT
      645 Mn
      YoY+49%
    • PAT Margin
      20%

    9M

    4
    • Consolidated Revenue
      8,534 Mn
      YoY+43%
    • Consolidated EBITDA
      2,716 Mn
      YoY+75%
    • Consolidated PAT
      1,655 Mn
      YoY+53%
    • PAT Margin
      19%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹450 crores

    Liquidity

    Liquidity disclosed

    Net working capital cycle increased to 160 days due to inventory buildup for Site 3++ and Site 5, which are expected to begin from March '26.

    Guidance & targets

    8
    CategoryTargetPriority
    Business Mix
    Revenue contribution from CRAMS and CEM
    70%
    High
    Business Mix
    Revenue contribution from large scale manufacturing
    30%
    High
    Margin
    Sustainable EBITDA margin
    29-30%
    High
    Capacity Utilization
    Site 3++ capacity utilization
    45-50%
    High
    Capacity Utilization
    Site 5 (2 blocks) capacity utilization
    35-40%
    High
    Product Commercialization
    Converge polyol capacity
    2 KTA (2,000 tonnes)
    Medium
    Product Commercialization
    Milliken-sized molecules converting to significant contracts
    3-4 molecules
    Medium
    Sales Target
    Otsuka Chemical sales
    INR35-40 crores
    High

    Site 3++ Commercial Production

    shortly (March '26)
    CurrentConstruction and trials completed
    TargetCommercial production commenced

    Why it matters

    Crucial for new capacity utilization and revenue generation from expansion projects.

    I'm delighted to inform you that the construction and installation of Site 3++ and the first 2 production blocks of Site 5 has been completed and water plus and solvent trials have been commenced. Commercial production from these sites will comment shortly.

    How to verify

    detailed_narrative[title='Capacity Expansion & Commercialization']

    Risks & concerns

    3
    RiskSeverity

    Volatile Macro Environment

    Global environment continues to remain volatile, but customer inquiries are increasing.Management acknowledged

    medium

    China Competition and Pricing Pressure

    LSM business faces aggressive payment terms from China. Lithium-ion battery chemical project put on hold due to aggressive pricing from China. Management will monitor China's pricing post-holidays.Both acknowledged

    medium

    Increased Working Capital Cycle

    Working capital cycle increased to 160 days due to inventory buildup for new plants (Site 3++ and Site 5) starting commercial production in March '26, considered temporary.Management acknowledged

    low

    Q&A highlights

    8

    “We lead from the top. We are family and our promoter family is a mix of techno-commercial excellence. Our Chairman and Managing Director, Ashwin Desai, our father, is a chemical engineer. I am a chemical engineer by bachelor's, and a PhD in organic chemistry, and so we lead from the top, especially when there are problems. We are very, very involved.”

    Highlights management's proactive approach to talent management and the company's culture of leadership involvement and acceptance of R&D outcomes.

    asked by Sajal Kapoor

    3 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Aether Industri. reported strong financial performance for Q3 FY26, with consolidated revenue from operations increasing by 44% YoY to INR3,171 million. EBITDA saw a significant 75% YoY growth, reaching INR1,083 million, and the EBITDA margin expanded to 34% from 28% in Q3 FY25. Net profit after tax (PAT) also grew by 49% YoY to INR645 million, resulting in a PAT margin of 20% for the quarter. For the nine months ended December 31, 2025, revenue increased 43% to INR8,534 million, EBITDA grew 75% to INR2,716 million, and PAT rose 53% to INR1,655 million.

    02

    Capacity Expansion and Commercialization Progress

    The company announced the completion of construction and installation for Site 3++ and the first two production blocks of Site 5. Water and solvent trials have commenced, with commercial production from these sites expected to begin shortly, specifically from March 2026. The total CWIP for Site 3++ and Site 5 amounted to approximately INR500 crores in the first nine months of FY26. For FY27, Site 3++ is targeted for 45-50% capacity utilization, while the two blocks of Site 5 are expected to achieve 35-40% utilization.

    03

    Business Vertical Performance and Outlook

    In Q3 FY26, sales composition included 43% from contracts plus exclusive manufacturing, 41% from large-scale manufacturing, and 8% from contract research and manufacturing services. Large-scale manufacturing demonstrated robust volume growth of over 10% QoQ and 25% YoY. Sales from Site 4 increased 20% QoQ to INR60 crores. The company expects the share of Oil and Gas (22%) and Material Science (18%) sectors to scale up by year-end, with a long-term target of 70% revenue from CRAMS/CEM and 30% from large-scale manufacturing.

    04

    R&D and New Client Initiatives

    Aether is undertaking significant R&D expansion, including adding 20 fume hoods and engineering labs in the short term, and 15 additional labs with 150 fume hoods and advanced analytical equipment like NMR in the long term. This expansion focuses on chemical engineering for non-pharma, non-agro, oil and gas, and material science sectors. The company has secured a CEM exclusive contract with a European chemical company in the material science sector, which will utilize a modified production line in Site 3. Validation batches for electronic chemicals for the semiconductor industry, targeting Japan, South Korea, and Taiwan, have already been dispatched.

    05

    Working Capital and Margin Management

    The net working capital cycle increased to 160 days in Q3 FY26 from 149 days as of September 30, 2025. This increase is primarily attributed to inventory buildup in preparation for the commercial launch of Site 3++ and Site 5 in March 2026. Management maintains a conservative sustainable EBITDA margin guidance of 29-30%, noting that the reported 34% margin in Q3 FY26 was partially influenced by a one-time📎 FLOP claim of INR15 crores.

    06

    Strategic Partnerships and Outsourcing Advantages

    Management emphasized its strategy of building long-term strategic partnerships, particularly in the CEM segment, where it aims to be a 'go-to partner' and 'one-stop solution' for innovators. The company highlighted its competitive edge due to favorable Indian economics compared to the West, transparent costing models, and a commitment to long-term relationships (20 years, 10 projects in pipeline). Aether's focus on IP protection, trust, and executional innovation, coupled with redundant and fungible manufacturing sites, allows it to be a sole supplier for key clients like Baker Hughes.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.